Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

GSK has turned to China’s Hansoh Pharma to add another antibody ... making it an interesting target for therapy that could avoid off-target side effects. GSK said HS-20093 has already shown ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leading the charge include Pfizer, AstraZeneca, Viking Therapeutics, Merck & Hansoh Pharma ... assets for obesity and diabetes treatment. The acquisition strengthens Roche’s position in the ...